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Abstract Model organisms include yeast Saccromyces
cerevisae and fly Drosophila melanogaster. These systems
have powerful genetic approaches, as well as highly
conserved pathways, both for normal function and disease.
Here, we review and highlight how we applied these
systems to provide mechanistic insight into the toxicity of
TDP-43. TDP-43 accumulates in pathological aggregates in
ALS and about half of FTD. Yeast and fly studies revealed
an interaction with the counterparts of human Ataxin-2, a
gene whose polyglutamine repeat expansion is associated
with spinocerebellar ataxia type 2. This finding raised the
hypothesis that repeat expansions in ataxin-2 may associate
with diseases characterized by TDP-43 pathology such as
ALS. DNA analysis of patients revealed that intermediate-
length polyglutamine expansions in ataxin-2 are a risk
factor for ALS, such that repeat lengths are greater than
normal, but lower than that associated with spinocerebellar
ataxia type 2 (SCA2), and are more frequent in ALS
patients than in matched controls. Moreover, repeat
expansions associated with ALS are interrupted CAA-
CAG sequences as opposed to the pure CAG repeat
expansions typically associated with SCA2. These studies
provide an example of how model systems, when extended
to human cells and human patient tissue, can reveal new
mechanistic insight into disease.
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Introduction
Human Neurodegenerative Disease and its Challenges
Human neurodegenerative diseases include disorders such
as Alzheimer’s disease, Parkinson’s disease, amyotrophic
lateral sclerosis (ALS), and frontotemporal lobular demen-
tia (FTLD; for recent reviews, see Lagier-Tourenne and
Cleveland 2009; Chen-Plotkin et al. 2010; Dawson et al.
2010; Reitz et al. 2011). Although these diseases are
typically sporadic in nature, familial forms exist that allow
the identification of key gene products that may be
involved in both familial as well as sporadic situations. In
addition, it is often the case that the protein products of
genes in which mutations can be associated with disease are
also found to accumulate abnormally in at least some
percentage of the disease situations. For example, rare
mutations in alpha-synuclein are associated with familial
Parkinson’s disease, and sporadic Parkinson’s disease is
typified by Lewy bodies comprised of alpha-synuclein. The
abnormal accumulation of Tar DNA-binding protein of
43 kD (TDP-43) typifies most ALS and about half of FTLD
(FTLD-TDP), and mutations in TDP-43 occur in ALS and
in rare cases of FTLD (Lagier-Tourenne and Cleveland
2009; Chen-Plotkin et al. 2010). Further, these studies
highlight the notion that the abnormal accumulation, and/or
localization of such gene products, associates with disease
and may be causal. These types of findings pave the way
for modeling such disorders in other simpler systems.
Whereas such systems include human or mammalian cells
in culture and the mouse, more fundamental model
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organisms such as yeast and Drosophila have extremely
powerful techniques that can be brought to bear on these
problems. Here, we focus on our recent insights revealed by
yeast and fly in the study of TDP-43 toxicity.
Model Organisms Bring Insight into Human Disease
Model organisms include systems such as the simple yeast,
fly, and nematode. These systems have highly manipulable
and very powerful genetic approaches, which allow insight
to be elucidated, and in relatively rapid form, into
fundamental gene pathways and protein functions. Classi-
cally, these systems have been used to approach key
problems, such as cell cycle or secretion (for example,
yeast; Nurse 2002; Luzio et al. 2007), and gene function
and impact in development (fly and nematode; Putcha and
Johnson 2004; Bier 2005). However, their strengths extend
well beyond these basic “normal” processes and into
disease. With the elucidation of the genomes of these
organisms and network interactions, it has become clear
that many genes in many different processes are highly
conserved with humans (Adams et al. 2000; Boone et al.
2007). This means that these simpler systems can be
employed to provide insight into those features that are
shared in a process between these systems and the more
complex and more difficult to study human situation.
Moreover, the impact of model organisms is not limited to
normal aspects of development, but one can “re-create”
certain aspects of a human disease in these simple systems
(Jackson et al. 1998; Warrick et al. 1998; Feany and Bender
2000; Cooper et al. 2006; Johnson et al. 2008). This then
allows use of the simpler systems as a launching ground to
define key pathways and processes of relevance to the far
more complex disease in humans. The key points into
generating models for human disease include that many
human neurodegenerative diseases are thought to be
associated with gain-of-function activities due to the
accumulation of the protein of interest. This means that
by expressing the wild-type or disease-associated mutant
version of the protein linked to the human disease, one
hopes to recapitulate aspects of the toxicity of the protein.
Although the disease in humans may be complex, and may
comprise both gain-of-function as well as loss-of-function
aspects of the disease protein, it is possible to get a handle
on features of the toxicity of the disease protein.
The strength of simple model organisms for providing
“genome-wide” insight into the disease process cannot be
overstated. For example, the yeast genetics armamentarium
is bafflingly powerful: entire libraries exist of every gene of
the genome knocked out or upregulated. Thus, once a
model is in hand, one can assess the effects of changing
gene dosage of every gene of the genome. For Drosophila,
the large collections of upregulation or reduced gene
activity lines exist, which can similarly be used to assess
for activity on the disease effect in the fly. Whereas, yeast
has the advantage of a single cell, allowing a simple view
of processes and pathways, Drosophila offers the added
complexity and interactions of neurons, and integrity of the
nervous system and brain with age.
Yeast as a Model for Human Disease: Special Insights
into TDP-43 Toxicity
To provide a foundation for yeast to reveal insight into
TDP-43 toxicity, the human gene, tagged for ready
visualization with fluorescent YFP, was expressed in yeast
using a conditional system (Johnson et al. 2008). The
expression of TDP-43 at low levels causes the protein to be
nuclear, with occasional foci formation; markedly, expres-
sion at higher levels dramatically shifts the localization to
the cytoplasm with notable foci. Intriguingly, in ALS and
FTLD-TDP, TDP-43, which is normally nuclear, is now
seen also in the cytoplasm forming round or skein-like
inclusions (Neumann et al. 2006). Thus, aggregation of the
protein can be modeled in yeast.
Although accumulation of TDP-43 is noteworthy in
disease, the consequences were unclear. But strikingly in
yeast, TDP-43 is toxic, leading to loss of growth of the cells
(Johnson et al. 2008). This fundamental finding thus
provides the foundation for many additional derivative
experiments to explore and define features of the toxicity.
For example, what domains of the TDP-43 protein are
necessary and sufficient for toxicity? Intriguingly, these
studies identify the predicted RNA-binding RRM2 domain
and the prion-like C-terminal glycine-rich tail as central
(Johnson et al. 2008; Cushman et al. 2010). Notably, most
human mutations associated with disease are localized to
the C-terminal domain (Lagier-Tourenne and Cleveland
2009). These studies also dissociate aggregation of the
protein from toxic interactions, by demonstrating that
aggregation into foci is not sufficient for toxicity in yeast.
More detailed study reveals that C-terminal mutations
associated with ALS accelerate the aggregation of the protein
in yeast, such that most mutations present with a greater
number of foci at the same time point, compared to the wild-
type version of the protein (Johnson et al. 2009). Compelling
additional data raise the hypothesis that proteins like TDP-
43, and another protein associated with ALS, FUS, have
domains that are prion-like in nature, being rich in nonpolar
amino acids, asparagine, glutamine, and tyrosine (Cushman
et al. 2010). Perhaps this is a common feature of proteins
associated with human neurodegenerative disease, because
of their propensity to form aggregates.
Notably, different human neurodegenerative disease
proteins, when expressed in yeast, can cause toxicity. For
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example, both alpha-synuclein (Cooper et al. 2006) and
TDP-43 (Johnson et al. 2008) cause a failure of growth.
Superficially, these proteins act in a similar way, in that
both proteins aggregate and are toxic in yeast. However, the
network of interactions underscores that the nature of the
toxicity is distinct: a comparison of genome-wide modifiers
of alpha-synuclein toxicity and TDP-43 toxicity show little
overlap (Cooper et al. 2006; Gitler et al. 2009; Yeger-Lotem
et al. 2009; Elden et al. 2010). As with any such network,
the challenge then becomes determining what the network
of interacting proteins is revealing, and which one or ones
are worthy of aggressive focus.
Drosophila as a Model for Human Disease:
Special Insights into Disease Processes
Drosophila is a complex organism, complete with a
functioning nervous system and brain, capable of many
behaviors like learning, motility, and visual acuity. This
system has become popular for the study of human
neurodegenerative disease proteins (Shulman et al. 2003;
Bilen and Bonini 2005; Marsh and Thompson 2006). Select
techniques or types of analyses can be emphasized to
highlight those features that reflect the human disease
situation, thus tailoring the approach. Typically, to achieve
expression mimicking a gain-of-function human neurode-
generative disease situation, the protein of interest is
upregulated in the fly. One of the standard systems used
is the GAL4-UAS approach, where the gene of interest is
selectively driven in select tissues using GAL4 drivers
(drivers that direct expression to the eye, or nervous system,
or even a particular class of neuron; Brand and Perrimon
1993). This is a gain-of-function approach that can also be
combined with loss of gene function approaches in order to
explore whether the toxicity of the protein is pure gain of
function or is coupled with reduced activity, as well. These
types of experiments can also address whether the human
protein is able to confer function in the Drosophila system
by replacing the Drosophila gene. Behaviors that are
typically assessed include lifespan of the animal: does the
protein cause reduced survival with age? Motility of the
animal: does the protein cause more rapid loss of climbing
function with age? One can also compare toxicity of
different versions of the same protein expressed at the
same level: are mutations in TDP-43 more toxic than the
wild-type protein? Does the protein accumulate abnormally,
as in the human disease, and in the cytoplasm or nucleus?
Does manipulating its localization matter? Finally, a
common tissue to assess is the eye of the fly, simply for
the genetic applications. The eye has the advantage of being
nonessential to the organism, but highly manipulable and
readily scored in screens for greater or lessened toxicity, if
the protein has an effect on the external structure. Thus, by
combining these various techniques and approaches, and
comparing the range and the type of effects with the human
disease, one can establish a model that reflects fundamental
features of the disease.
A number of models for TDP-43 toxicity in flies have been
generated (Elden et al. 2010; Li et al. 2010; Ritson et al.
2010; Voigt et al. 2010), revealing that the protein shows
toxicity in vivo. Indeed, the upregulation of wild-type TDP-
43, or the Q331K mutant, causes progressive degeneration in
the eye, coupled with the loss of motility and lifespan when
expressed in the nervous system or directed to motor neurons
(Elden et al. 2010). Interestingly, the loss of TDP-43 also
causes deficits (Feiguin et al. 2009), suggesting that a careful
analysis of TDP-43 toxicity should ultimately include both
studies to reveal gain-of-function activities, as well as loss-
of-function effects.
Ataxin-2 is a Modifier of TDP-43 Toxicity
Combining the power of yeast and fly promises to reveal
those pathways of disease that overlap and that are most
conserved. Thus, to gain insight into mechanisms of TDP-
43 pathogenesis, an unbiased genetic approach was used in
yeast to identify genes that could suppress or enhance TDP-
43 toxicity (Elden et al. 2010). The largest functional class
enriched in the screen included RNA-binding proteins and
proteins involved in RNA metabolism, and revealed
minimal overlap with alpha-synuclein modifiers. Thus, the
modifiers address the selective biology of the disease
proteins (e.g., vesicle trafficking for alpha-synuclein and
RNA biology with TDP-43), informing insight into
pathology in disease.
One gene identified that enhanced TDP-43 toxicity, PBP1
(poly(A)-binding protein, (Pab1p)-binding protein), was of
immediate interest, as it is the yeast homologue of human
ataxin-2, a polyglutamine protein mutated in the human
neurodegenerative disease spinocerebellar ataxia type 2
(SCA2; Fig. 1a). Although SCA2 primarily presents with
cerebellar Purkinje neuron degeneration, as in ALS, motor
neurons can also degenerate, although these features are
typically later than the cerebellar degeneration. In select
cases, however, the motor neuron features can be sufficiently
prominent to mimic an ALS presentation (Infante et al. 2004;
Nanetti et al. 2009). These findings raise the potential for
mechanistic overlap between SCA2 and ALS. Ataxin-2, like
yeast Pbp1, is likely involved in aspects of RNA metabolism
(Mangus et al. 1998; Lastres-Becker et al. 2008). Notably,
Pbp1 is a dose-sensitive modifier of TDP-43 toxicity in
yeast, with upregulation enhancing and loss of function
suppressing TDP-43 toxicity. These data indicate that the
genes are critical interacting components.
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Drosophila can reveal the relevance to the intact, function-
ing nervous system (Fig. 1b). Thus potential interactions
between TDP-43 and ataxin-2 were extended to the fly.
Moreover, the fly also has an ataxin-2 homologue, thus one
can assess dose-sensitive interactions with the endogenous
gene. As noted above, TDP-43 causes retinal degeneration,
loss of motility, and reduced lifespan. Remarkably, testing for
interactions with the fly ataxin-2 revealed that upregulation of
the fly gene dramatically potentiated toxicity of TDP-43,
leading to more severe retinal degeneration, further shortening
of lifespan, and causing more rapid loss of motility (Fig. 1b;
Elden et al. 2010). Strikingly, reduction of ataxin-2 also had a
dramatic effect, in this case to mitigate toxicity, extending
lifespan to nearly normal levels. Thus, these findings indicate
that the modulation of TDP-43 toxicity by ataxin-2 extends to
the nervous system, where it is exquisitely sensitive to the
levels of ataxin-2.
These studies were extended to assess the interaction
between the two proteins in cells in culture and patient tissue
(Elden et al. 2010). In HEK293T cells, TDP-43 is normally
nuclear, but targeting the protein to the cytoplasm leads to
foci formation. These foci co-localize with ataxin-2. Further,
upregulated TDP-43 interacts with endogenous ataxin-2
protein by co-immunoprecipitation. This interaction, by co-
immunoprecipitation or immunocytochemistry, is dependent
upon the RNA-binding capacity of the protein, as revealed by
point mutation of the RRM domains in the TDP-43 protein.
Further, the toxicity in yeast is similarly dependent upon the
RNA-binding capacity of the protein. Thus, these findings
indicate the proteins interact biologically by genetic and
biochemical approaches, and that the RNA-binding activities
of TDP-43 are important for these interactions.
Analysis of postmortem spinal cord sections of ALS patients
and controls further support an interaction. First, ataxin-2 is
robustly expressed in spinal cord motor neurons, as is TDP-43.
Second, although ataxin-2 is normally localized in a diffuse or
fine granular pattern, in ∼30% of motor neurons of ALS
patients, ataxin-2 shows larger, more distinct accumulations
(Fig. 2; Elden et al. 2010). Finally, ataxin-2 can be seen to
overlap with TDP-43 immunostaining in cortical inclusions in
FTLD-TDP, although not in the spinal cord in ALS.
Ataxin-2 Intermediate-Length PolyQ Expansions
Are a Risk Factor for ALS
Our initial interest in ataxin-2 was spurred by an understand-
ing of the mutations in ataxin-2 that are associated with human
disease. That is, ataxin-2 bears a polyglutamine repeat that,
upon expansion, causes SCA2 disease. However, there is a
Fig. 1 TDP-43 is toxic to yeast
and fly, and ataxin-2 enhances this
toxicity. a Pbp1, the yeast homo-
logue of ataxin-2, is a dose-
sensitive modifier of TDP-43
toxicity in yeast. Fivefold serial
dilutions of yeast cells spotted
onto glucose (expression re-
pressed) or galactose (expression
induced). Spotting assays with
yeast expressing TDP-43 show-
ing toxicity. Upregulation of
PBP1 enhances TDP-43 toxicity.
b Ataxin-2 is a modifier of TDP-
43 toxicity in the nervous system
of Drosophila. Flies expressing
TDP-43 or dAtx2 alone (dAtx2EP)
in the eye (with gmr-GAL4
driver) have a mild effect on
retinal structure. TDP-43 toxicity
is more severe upon upregulation
of dAtx2 (dAtx2EP). TDP-43 tox-
icity is markedly mitigated upon
the reduction of dAtx2 (flies in
trans to null allele dAtx2X1). The
figure and the legend are from
Elden et al. (2010)
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gap between the polyglutamine length of normal and SCA2.
The polyglutamine tract length in ataxin-2 is most frequently
22–23, with expansions of greater than 34 being associated
with SCA2 (Imbert et al. 1996; Pulst et al. 1996; Sanpei et al.
1996; Lorenzetti et al. 1997). Thus, could it be that polyQ
repeat lengths that are greater than normal, but below the
threshold for SCA2, are associated with ALS?
Genescan analysis was used to define ataxin-2 polyglut-
amine repeat lengths in genomic DNA from more than 900
individuals diagnosed with ALS and a similar number of
ethnically and geographically matched neurologically normal
controls. This analysis revealed an association between longer
repeat lengths (>26–33) in ataxin-2 and ALS (Fig. 3).
Detailed analysis determined that whereas only 1.4% of
controls bear a single intermediate-length ataxin-2 allele,
4.7% of ALS patients had one allele with an intermediate-
length ataxin-2 repeat. These included both sporadic and
familial disease cases. Notably, in 980 neurologically normal
controls, only three individuals had expansions >28 (all three
were under the age of 60), whereas 24 ALS cases fell in that
range. These studies therefore indicated that intermediate-
length ataxin-2 polyglutamine repeat lengths are significantly
associated with risk for ALS.
The extension of these findings to other populations
indicates that an association between longer polyglutamine
repeats in ataxin-2 and ALS also occurs, although the
frequency and precise repeat length cutoff appears depen-
dent on the specific population. Thus, in Europeans, there is
also an increased risk for ALS with longer polyglutamine
repeats in ataxin-2; however, the repeat length cutoff is
greater than 30 glutamines, such than 1% of the patients
harbor such repeats (Lee et al. 2011b).
Detailed studies reveal insight into the interaction between
the two proteins, as well as complexities that may underlie
Fig. 2 Ataxin-2 shows altered localization in spinal cord motor
neurons of ALS patients. Immunostaining for ataxin-2 in spinal cord.
a, b In control spinal cord neurons, ataxin-2 is localized throughout
the cytoplasm in a diffuse pattern. c, d In ALS spinal cord neurons,
ataxin-2 was present in distinct cytoplasmic accumulations (arrows).
In some cases, ataxin-2 positive accumulations were adjacent to
clearings indicative of TDP-43 aggregates (asterisk in b). The figure
and the legend are from Elden et al. (2010)
Fig. 3 Ataxin-2 intermediate-length polyglutamine repeat expansions
are associated with increased risk for ALS. The ATXN2 gene contains
a trinucleotide repeat encoding polyglutamine. The repeat length is
normally 22–23Q. Expansions of >34 cause SCA2. We hypothesized
that the intermediate-length polyglutamine expansions could be linked
to ALS. The ataxin-2 polyglutamine length was defined by Genescan
analysis of ALS cases and neurologically normal controls. a The
distribution of ataxin-2 polyglutamine repeat lengths in ALS and
control cases. Polyglutamine lengths ≥27 are significantly enriched in
ALS. Further, polyQ lengths >31 were never observed in our controls,
but we found ten ALS patients above this threshold. b Representative
examples of Genescan analysis of polyglutamine lengths from control
and ALS cases. The figure and the legend are from Elden et al. (2010)
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disease. Both TDP-43 and ataxin-2 can localize to stress
granules and interact with stress granule components (Nonhoff
et al. 2007; Liu-Yesucevitz et al. 2010). Thus, it stands to
reason that the proteins may interact in stress granules and
notably, that one catalyst for interaction may be stress.
Strikingly, heat shock induces some TDP-43 to accumulate
in the cytoplasm of cells normally; in beta-lymphoblasts
derived from controls versus ALS patients with normal and
expanded ataxin-2 repeat lengths, stress induces a greater
percentage of cells to accumulate TDP-43 in the cytoplasm
(Elden et al. 2010). The fly and yeast gene dosage data
suggest that ataxin-2 and TDP-43 normally interact, and
together with cellular data, these interactions may become
more severe upon ataxin-2 repeat expansions and stress.
Ataxin-2 also presents a fascinating human disease gene
because it can present with multiple clinical presentations.
Expansions greater than 34 are associated with SCA2, and we
have suggested that repeats that are greater than normal, but less
than that associated with SCA2, are a genetic risk factor for
ALS. However, expansions in ataxin-2 can also present
atypically with parkinsonism (Giunti et al. 1998; Gwinn-
Hardy et al. 2000; Shan et al. 2001; Furtado et al. 2002; Lu et
al. 2004; Ragothaman et al. 2004; Boone et al. 2007; Modoni
et al. 2007; Socal et al. 2009). Intriguingly, it has been noted
in at least some of these situations that the repeat expansions in
the gene encoding ataxin-2 may be interrupted CAG expan-
sions versus the pure CAG repeat expansions of SCA2. That is,
expansions in ataxin-2 associated with SCA2 are typically pure
CAG repeat expansions, whereas those associated with
parkinsonism have been noted to be CAA or other codon
interruptions (Gwinn-Hardy et al. 2000). Since CAG and CAA
codons both specify the amino acid glutamine, it suggests the
intriguing possibility that the particular configuration of the
RNA encoding the polyglutamine tract can also play a role in
pathogenesis. This raises the question whether the repeat
expansions in ataxin-2 associated with ALS are pure CAG
repeats or interrupted repeats. Notably, pure CAG repeat
expansions can confer toxicity on their own (Li et al. 2008);
the mechanisms are of great interest and may include
interactions with select proteins and noninitiation-dependent
translation (Li and Bonini 2010; Zu et al. 2011). Analysis of
the repeat sequences in alleles associated with increased risk
for ALS reveals that the repeats are interrupted, thus not pure
CAG repeats (Yu et al. 2011). Thus, the integration of RNA-
based toxicity due to the RNA encoding the disease protein,
as well as protein-based effects, may be involved.
Conclusions/Future Perspectives
The application of model organism strengths to the
problems of human disease have allowed insight into
numerous pathways and processes that go awry in disease,
as well as allowed focus for disease therapeutics. Of course,
not all aspects of the disease will be recapitulated, as these
systems have fewer genes and less complexity including in
the nervous system. However, the use of these systems will
allow focus on those pathways that are conserved, allowing
a key insight into the fundamental processes affected. These
studies to reveal insight into TDP-43 using yeast and fly
have highlighted an important new player in ALS in ataxin-2.
Does ataxin-2 also play a role in FTD, where TDP-43 is also
prominent? Does ataxin-2 also play a role in other human
diseases, such as Parkinson’s and Alzheimer’s diseases, which
can have clinical overlaps and also show protein pathological
overlaps? What about other polyglutamine disease genes in
ALS? Our studies have revealed a lack of association of
expanded polyglutamine repeat lengths in other polyglut-
amine genes in ALS, indicating specificity to ataxin-2 (Lee et
al. 2011a). However, it remains possible that normal
activities of other polyglutamine disease proteins intersect
in ALS. The integration of model organism studies with
human pathological insight will reveal key gene nodes that
underlie many of these diseases, defining central players to
attack therapeutically. Future studies are focused on detailed
assessment of the interactions between TDP-43, ataxin-2,
and the combined toxicity, as well as more insight into other
pathways and processes affected. With such approaches, and
the combined insight of genome wide association studies and
next generation sequencing approaches, we anticipate re-
vealing all the genes that can contribute to these diseases
soon, with the following challenge to determine how the
pathways intertwine and overlap, and go awry in disease.
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